{"id":483959,"date":"2010-03-29T07:00:58","date_gmt":"2010-03-29T11:00:58","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=70282"},"modified":"2010-03-29T07:00:58","modified_gmt":"2010-03-29T11:00:58","slug":"avila-teams-with-leukemia-society","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/483959","title":{"rendered":"Avila Teams With Leukemia Society"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/cancer\/\">cancer<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p><a href=\"http:\/\/www.avilatx.com\/\">Avila Therapeutics<\/a>, the Waltham, MA-based drug developer, is announcing today it will receive as much as $3.2 million from The Leukemia &amp; Lymphoma Society to support development of a new therapy for B-cell related cancers. The drug, AVL-292, is designed to form a tight covalent bond to hit a target on immune system B-cells, called Bruton&#8217;s Tyrosine Kinase, or Btk. Avila plans to take the product candidate into its first clinical trial in 2010. Avila CEO Katrine Bosley told me more about this drug and Avila&#8217;s hepatitis C treatment, <a href=\"http:\/\/www.xconomy.com\/boston\/2010\/02\/26\/avila-aims-to-trump-vertex-with-drug-that-hits-hepatitis-c-virus-and-wont-let-go\/\">in a feature story last month<\/a>.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/29\/avila-teams-with-leukemia-society\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Avila%20Teams%20With%20Leukemia%20Society%20http:\/\/xconomy.com\/?p=70282\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/29\/avila-teams-with-leukemia-society\/&#038;t=Avila%20Teams%20With%20Leukemia%20Society\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/29\/avila-teams-with-leukemia-society\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Avila+Teams+With+Leukemia+Society&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F29%2Favila-teams-with-leukemia-society%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=fc0eec805ec04acca6f61e9bdab02957&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=fc0eec805ec04acca6f61e9bdab02957&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/ibY6O-zFh3PygT5xAfSoYs0Gvok\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/ibY6O-zFh3PygT5xAfSoYs0Gvok\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/ibY6O-zFh3PygT5xAfSoYs0Gvok\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/ibY6O-zFh3PygT5xAfSoYs0Gvok\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/iKXUSuDQjhM\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, deals, cancer Luke Timmerman wrote: Avila Therapeutics, the Waltham, MA-based drug developer, is announcing today it will receive as much as $3.2 million from The Leukemia &amp; Lymphoma Society to support development of a new therapy for B-cell related cancers. The drug, AVL-292, is designed to form a tight covalent bond to hit a [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-483959","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/483959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=483959"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/483959\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=483959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=483959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=483959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}